umberto vitolo
umberto vitolo
Hematology Consultant, Candiolo Cancer Institute, FPO-IRCCS, Candiolo (Torino), Italy
Verified email at
Cited by
Cited by
Follicular lymphoma international prognostic index
P Solal-Céligny, P Roy, P Colombat, J White, JO Armitage, R Arranz-Saez, ...
Blood 104 (5), 1258-1265, 2004
Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
H Tilly, MG Da Silva, U Vitolo, A Jack, M Meignan, A Lopez-Guillermo, ...
Annals of oncology 26, v116-v125, 2015
Early Interim 2-[18F]Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Is Prognostically Superior to International Prognostic Score in Advanced-Stage …
A Gallamini, M Hutchings, L Rigacci, L Specht, F Merli, M Hansen, C Patti, ...
Journal of clinical oncology 25 (24), 3746-3752, 2007
Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project
M Federico, M Bellei, L Marcheselli, S Luminari, A Lopez-Guillermo, ...
Journal of Clinical Oncology 27 (27), 4555-4562, 2009
Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study
A Gallamini, C Stelitano, R Calvi, M Bellei, D Mattei, U Vitolo, F Morabito, ...
Blood 103 (7), 2474-2479, 2004
Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†☆
M Dreyling, M Ghielmini, S Rule, G Salles, M Ladetto, SH Tonino, ...
Annals of Oncology 32 (3), 298-308, 2021
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
S Horwitz, OA O'Connor, B Pro, T Illidge, M Fanale, R Advani, NL Bartlett, ...
The Lancet 393 (10168), 229-240, 2019
Patterns of outcome and prognostic factors in primary large cell lymphoma of the testis in a survey of 373 patients by the International Extranodal Lymphoma Study Grfoup (IELSG).
E Zucca, A Conconi, TI Mughal, AH Sarris, JF Seymour, U Vitolo, R Klasa, ...
Journal of Clinical Oncology 21, 20-27, 2003
Phase III trial of consolidation therapy with yttrium-90–ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma
F Morschhauser, J Radford, A Van Hoof, U Vitolo, P Soubeyran, H Tilly, ...
Journal of Clinical Oncology 26 (32), 5156-5164, 2008
ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned
S Viviani, PL Zinzani, A Rambaldi, E Brusamolino, A Levis, V Bonfante, ...
New England Journal of Medicine 365 (3), 203-212, 2011
Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma.
U Vitolo, M Trněný, D Belada, JM Burke, AM Carella, N Chua, ...
Journal of clinical oncology: official journal of the American Society of …, 2017
The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease
A Gallamini, L Rigacci, F Merli, L Nassi, A Bosi, I Capodanno, S Luminari, ...
haematologica 91 (4), 475-481, 2006
Hypermethylation of the DNA Repair Gene O6-Methylguanine DNA Methyltransferase and Survival of Patients With Diffuse Large B-Cell Lymphoma
M Esteller, G Gaidano, SN Goodman, V Zagonel, D Capello, B Botto, ...
Journal of the National Cancer Institute 94 (1), 26-32, 2002
R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana …
M Federico, S Luminari, A Dondi, A Tucci, U Vitolo, L Rigacci, ...
Journal of Clinical Oncology 31 (12), 1506-1513, 2013
Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis …
M Ladetto, F De Marco, F Benedetti, U Vitolo, C Patti, A Rambaldi, ...
Blood, The Journal of the American Society of Hematology 111 (8), 4004-4013, 2008
Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP
P Pregno, A Chiappella, M Bellň, B Botto, S Ferrero, S Franceschetti, ...
Blood, The Journal of the American Society of Hematology 119 (9), 2066-2073, 2012
Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the …
E Zucca, A Conconi, D Laszlo, A López-Guillermo, R Bouabdallah, ...
J Clin Oncol 31 (5), 565-572, 2013
First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an …
U Vitolo, A Chiappella, AJM Ferreri, M Martelli, I Baldi, M Balzarotti, ...
Journal of Clinical Oncology 29 (20), 2766-2772, 2011
Distribution and pattern of BCL-6 mutations throughout the spectrum of B-cell neoplasia
D Capello, U Vitolo, L Pasqualucci, S Quattrone, G Migliaretti, L Fassone, ...
Blood, The Journal of the American Society of Hematology 95 (2), 651-659, 2000
Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma
M Dreyling, F Morschhauser, K Bouabdallah, D Bron, D Cunningham, ...
Annals of Oncology 28 (9), 2169-2178, 2017
The system can't perform the operation now. Try again later.
Articles 1–20